This is a preview of subscription content, log in via an institution to check access.
Notes
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
2017 US dollars
References
Fonarow GC, et al. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology : 23 Aug 2017. Available from: URL: http://dx.doi.org/10.1001/jamacardio.2017.2762.
Mark DB, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy--Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiology : 23 Aug 2017. Available from: URL: http://dx.doi.org/10.1001/jamacardio.2017.2911.
Rights and permissions
About this article
Cite this article
Evolocumab not cost effective for ASCVD at current US price. PharmacoEcon Outcomes News 786, 15 (2017). https://doi.org/10.1007/s40274-017-4305-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4305-0